EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER

@article{Cantillon2014EFFICACYAS,
  title={EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER},
  author={Marc Cantillon},
  journal={Schizophrenia Research},
  year={2014},
  volume={153}
}
  • M. Cantillon
  • Published 1 April 2014
  • Psychology
  • Schizophrenia Research

RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline‐induced pulmonary arterial hypertension in rats

Pharmacological treatment of schizophrenia – a review of progress

The authors discuss the situation where there is no single pharmacological agent on the horizon that could serve as the ‘holy grail’ to address the full range of symptoms of schizophrenia and what the immediate future holds with the widespread use of polypharmacy.

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, 
Present and Future

Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systematically reviewed and compared by reviewing structure-activity relationships, pharmacokinetic properties, drug metabolism and safety, pharmacological properties, preclinical data in animal models, clinical outcomes and associated side effects.

Pharmacological treatment of schizophrenia – a review of progress

The authors discuss the situation where there is no single pharmacological agent on the horizon that could serve as the ‘holy grail’ to address the full range of symptoms of schizophrenia and what the immediate future holds with the widespread use of polypharmacy.